tradingkey.logo

Standard BioTools Inc

LAB
View Detailed Chart

1.410USD

+0.060+4.44%
Close 09/18, 16:00ETQuotes delayed by 15 min
538.19MMarket Cap
LossP/E TTM

Standard BioTools Inc

1.410

+0.060+4.44%
Intraday
1m
30m
1h
D
W
M
D

Today

+4.44%

5 Days

+6.02%

1 Month

+11.02%

6 Months

+21.55%

Year to Date

-19.43%

1 Year

-30.54%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
76 / 207
Overall Ranking
198 / 4721
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 3 analysts
Buy
Current Rating
1.775
Target Price
+31.48%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Standard BioTools Inc. develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines. The Company's segments include Proteomics and Genomics. The Proteomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of genes and their functions. The Company provides insights in health and disease using its mass cytometry and microfluidics technologies, which serve applications in proteomics and genomic. It works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories around the world, focusing on the needs in translational and clinical research, including oncology, immunology, and immunotherapy. The Company also provides differentiated multi-omics tools for research.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 78.09% year-on-year.
Undervalued
The company’s latest PE is -4.57, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 283.64M shares, decreasing 9.05% quarter-over-quarter.
Held by Andreas Halvorsen
Star Investor Andreas Halvorsen holds 58.65M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.65.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Standard BioTools Inc. develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines. The Company's segments include Proteomics and Genomics. The Proteomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of genes and their functions. The Company provides insights in health and disease using its mass cytometry and microfluidics technologies, which serve applications in proteomics and genomic. It works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories around the world, focusing on the needs in translational and clinical research, including oncology, immunology, and immunotherapy. The Company also provides differentiated multi-omics tools for research.
Ticker SymbolLAB
CompanyStandard BioTools Inc
CEODr. Michael Egholm, Ph.D.
Websitehttps://www.standardbio.com/
KeyAI